Jennifer E Liu
Overview
Explore the profile of Jennifer E Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
2313
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Leong D, Waliany S, Abdel-Qadir H, Atkins K, Neilan T, Lang N, et al.
JACC CardioOncol
. 2025 Jan;
6(6):815-834.
PMID: 39801647
The administration of certain cancer therapies can be associated with the development of cardiovascular toxicity or complications. This spectrum of toxicities is broad and requires nuanced approaches for prevention, identification,...
2.
Tsay A, Satish M, Corley E, Ezema A, DeJesus N, Wisely S, et al.
Cardiooncology
. 2024 Oct;
10(1):70.
PMID: 39407287
Background: Trabectedin (Tbt) is an alkylating agent prescribed for soft tissue sarcomas after treatment failure of first line agents. While cardiomyopathy can occur with Tbt treatment after anthracycline exposure, Tbt-induced...
3.
Yu A, White C, Zhang Z, Liu J, Gillespie E, McCormick B, et al.
Adv Radiat Oncol
. 2024 Sep;
9(10):101581.
PMID: 39258142
Purpose: Regional nodal irradiation (RNI) for breast cancer yields improvements in disease outcomes, yet comprehensive target coverage often increases cardiac radiation therapy (RT) dose. Volumetric modulated arc therapy (VMAT) may...
4.
Shouval R, Goldman A, Flynn J, El-Moghraby A, Rehman M, Devlin S, et al.
Br J Haematol
. 2024 May;
205(3):978-989.
PMID: 38735683
Recent reports have raised concerns about the association of chimeric antigen receptor T cell (CAR-T) with non-negligible cardiotoxicity, particularly atrial arrhythmias. First, we conducted a pharmacovigilance study to assess the...
5.
Cheng R, Kittleson M, Wechalekar A, Alvarez-Cardona J, Mitchell J, Macedo A, et al.
Heart
. 2024 Jan;
110(12):823-830.
PMID: 38267197
The prevalence of amyloidosis has been increasing, driven by a combination of improved awareness, evolution of diagnostic pathways, and effective treatment options for both transthyretin and light chain amyloidosis. Due...
6.
Choe J, Byun A, Robinson E, Drake L, Tan K, McAleer E, et al.
Ann Surg
. 2023 Oct;
279(1):147-153.
PMID: 37800338
Objective: This study compared outcomes in patients with solid tumor treated for pericardial effusion with surgical drainage versus interventional radiology (IR) percutaneous drainage and compared incidence of paradoxical hemodynamic instability...
7.
Yu A, Lin I, Jorgensen J, Copeland-Halperin R, Feldman S, Ibtida I, et al.
J Am Heart Assoc
. 2023 Sep;
12(19):e029465.
PMID: 37750581
Background: Cancer therapy-related cardiac dysfunction (CTRCD) is an important treatment-limiting toxicity for patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer that adversely affects cancer and cardiovascular outcomes....
8.
Yu A, Moore Z, Moskowitz C, Liu J, Dang C, Ramanathan L, et al.
JAMA Cardiol
. 2023 May;
8(7):697-702.
PMID: 37256614
Importance: Cancer therapy-related cardiac dysfunction (CTRCD) is a potentially serious cardiotoxicity of treatments for ERBB2-positive breast cancer (formerly HER2). Identifying early biomarkers of cardiotoxicity could facilitate an individualized approach to...
9.
Mahmood S, Riedell P, Feldman S, George G, Sansoterra S, Althaus T, et al.
Eur Heart J
. 2023 Mar;
44(22):2029-2042.
PMID: 36939851
Aims: Chimeric antigen receptor T-cell therapy (CAR-T) harnesses a patient's immune system to target cancer. There are sparse existing data characterizing death outcomes after CAR-T-related cardiotoxicity. This study examines the...
10.
Yu A, Dang C, Jorgensen J, Moskowitz C, DeFusco P, Oligino E, et al.
Cardiooncology
. 2023 Mar;
9(1):13.
PMID: 36895062
Background: Echocardiograms are recommended every 3 months in patients receiving human epidermal growth factor 2 (HER2)-targeted therapy for surveillance of left ventricular ejection fraction (LVEF). Efforts to tailor treatment for...